Global Translational Regenerative Medicine Market Prospects 2017-2027

Friday, April 21, 2017 Drug News
Email Print This Page Comment
Font : A-A+

LONDON, April 21, 2017 /PRNewswire/ --

Stem Cell Therapies, Tissue Engineered Products,

Gene Therapies

The translational regenerative medicine market has been undergoing considerable changes over the last few years. There are a number of therapies that have been launched into the market over the last few years. Stem cell

therapies are being developed constantly and these are targeted at various indications, from the more common cardiovascular conditions to rarer orphan indications.

The Global Translational Regenerative Medicine market is expected to grow significantly over the forecast period. The Global Translational Regenerative Medicine market was valued at $5.8bn in 2016. Visiongain forecasts this market to increase to $14.5bn in 2021. The market is estimated to grow at a CAGR of 19.9% in the first half of the forecast period and 17.7% from 2016 to 2027.

How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new report you find 316-page report you will receive 107 tables and 66 figures - all unavailable elsewhere.

The 316-page report provides clear detailed insight into the Global Translational Regenerative Medicine market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope • Global Translational Regenerative Medicine market forecasts from 2017-2027

• Translational Regenerative Medicine regional market forecasts from 2017-2027, covering: - United States - Europe - Asia-Pacific - Rest of the World

• Global Translational Regenerative Medicine submarket forecasts from 2017-2027 covering: - Stem Cell Therapies - Tissue Engineered Products - Gene Therapies

• Forecasts from 2017-2027 of the leading products in the Global Translational Regenerative Medicine market: - Osteocel Plus - Trinity ELITE - TEMCELL /Prochymal - Apligraf - Dermagraft - Epifix - ReCell - Neovasculgen - Glybera (alipogene tiparvovec) - IMLYGIC (talimogene laherparepvec)

• Assessment of the leading companies in the Global Translational Regenerative Medicine market: - Alphatec Spine - Anterogen - Athersys - Avita Medical - AxoGen - Medipost - Mesoblast - NuVasive - Ocata Therapeutics - Organogenesis - Osiris Therapeutics - Pharmicell - Regenerys - TiGenix - UniQure - Vericel Corporation

• SWOT and Porter's Five Force analysis of the translational regenerative medicine market

Visiongain's study is intended for anyone requiring commercial analyses for the Translational Regenerative Medicine Market and leading companies. You find data, trends and predictions.

Buy our report today Global Translational Regenerative Medicine Market Prospects 2017-2027: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.

To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100

Or click on https://www.visiongain.com/Report/1843/Global-Translational-Regenerative-Medicine-Market-Prospects-2017-2027

The companies mentioned are:

Advanced BioHealing Advanced Tissue Sciences Advantagene AlloSource AlphaTec Spine Amedica Amgen Amorcyte Amorepacific Group AnGes MG Angioblast Systems Anika Therapeutics Anterogen Apceth Arcarios B.V Ark Therapeutics Athersys Inc Avita Medical AxoGen Baxter Beike Biotechnology Benda Pharmaceutical BioD Bioheart BioMed Realty Trust, Inc BioSante Pharmaceuticals BioTime BioTissue AG BioVex Inc Blackstone Medical BrainStorm Cell Therapeutics Caladrius Biosciences California Stem Cell Inc Capricor Cardio3BioSciences Celgene Cell Targeting CellCo Tec Cellerant Therapeutics Cephalon Ceregene CHA Biotech Chiesi Farmaceutici Cipla Co.don AG Cold Genesys Cook Biotech Inc Cytomedix Cytori Therapeutics Daiichi Sankyo DePuy Mitek (Johnson & Johnson) FibroCell Science Gamida Cell Ltd Genzyme Corporation (Sanofi) Histogenics Humacyte Human Stem Cell Institute Insulete Inc Interxon Corporation ISTO Technologies Janssen Biotech Inc Japan Tissue Engineering Co JCR Pharmaceuticals Johnson & Johnson Kinetic Concept Inc LecTec Corporation Lincoln Park Capital Lonza MacroCure Medipost Medtronic Mesoblast Mitsubishi Tanabe Myriad Genetics Neostem Neuralstem Nippon Zoki Pharmaceuticals NuVasive Ocata Therapeutics OncoCyte Organovo Orphan Biovitrum AB (Sobi) Orthofix Orteq Ltd. Osiris Therapeutics Oxford BioMedica Parcell Laboratories Pfizer Pharmicell Regenerys Reliance Life Sciences ReNeuron RTI Surgical Rusnano Corporation Sangamo Biosciences Sanofi Shanghai Sunway Biotech Shenzhen Sibiono GeneTech Shire Singapore General Hospital Skye Orthobiologics Smith & Nephewbv Sobi Partners Spark Therapeutics StemCells Inc. Stempeutics Research Stratatech Corporation TCA Cellular Therapy Tengion Inc Teva Pharmaceuticals TiGenix UniQure U.S. Stem Cell Inc. Vericel Corporation Viacyte Inc Vital Therapies WKD Holding Oy Xcellerex Xenetic Biosciences Zimmer

List of Organisations Mentioned in the Report Arthritis Research UK Associazione Infermieristica per lo Studio delle Lesioni Cutanee (AISLeC) [China] Australian Regenerative Medicine Institute Australian Sports Anti-Doping Authority (ASADA) Biomedical Advanced Research and Development Authority (BARDA) British Heart Foundation [UK] California Institute of Regenerative Medicine (CIRM) Cambridge Stem Cell Biology Institute [UK] Case Western Reserve University Catalan Institution for Research and Advanced Studies Center for Biologics Evaluation and Research (CBER) [US] CHA General Hospital [Korea] Cryocenter Saint Petersburg Drugs Controller General of India (DCGI) European Group for Blood and Marrow Transplantation (EBMT) European Medicines Agency Food and Drugs Agency (FDA) [US] Haute Autorité de santé [France] Heriot-Watt University Human Fertilisation and Embryology Authority (HFEA) Institute of Biomedical Research and Innovation Hospital [Japan] International Society for Stem Cell Research (ISSCR) Karolinska Institute [Sweden] Massachusetts General Hospital (MGH) Mayo Clinic [US] Medical Research Council [UK] MiMedx Ministry of Food and Drug Safety, MFDS) [Korea] Ministry of Health, Labour and Welfare (MHLW) [Japan] Ministry of Science and Technology [China] Moorfields Eye Hospital National Tissue Engineering Center (NTEC) [China] New York Blood Center Riken Center for Developmental Biology RUSH University Medical Center [US] Russian Ministry of Healthcare and Social Development Scottish Centre for Regenerative Medicine St. Jude's Children Research Hospital State Food and Drug Administration (SFDA) [China] SUNY Upstate Medical University The Genetico Center [Russia] The StemGen Organisation Therapeutics Goods Administration (TGA) [Australia] UH San Diego Sanford Stem Cell Clinical Center UK Medicines and Healthcare Products Regulatory Agency (MHRA) Universitat Autònoma de Barcelona [Spain] University College London University of Edinburgh MRC Centre for Regenerative Medicine [UK] University of Massachusetts (UMass) Memorial Hospital University of Modena Centre for Regenerative Medicine [Italy] University of Wisconsin US National Institute of Health Wake Forest Institute Wellcome Trust World Health Organization

To see a report overview please email Sara Peerun on sara.peerun@visiongain.com

SOURCE Visiongain Ltd



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook